OKYO Pharma CSO reports initial option holdings
OKYO Pharma Ltd reports that Chief Scientific Officer Rajkumar V. Patil holds common stock and multiple stock option awards as of March 18, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
OKYO Pharma Ltd reports that Chief Scientific Officer Rajkumar V. Patil holds common stock and multiple stock option awards as of March 18, 2026. Direct common stock holdings total 16,667 shares. The options cover various grants over common stock with exercise prices between $1.46 and $2.75, including tranches such as 59,615 and 23,126 underlying shares, with expirations from 2033 through 2035.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Common stock | -- | -- | -- |
Key Figures
Key Terms
conversion_or_exercise_price financial
underlying_security_title financial
expiration_date financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who is the insider in OKYO (OKYO) covered by this Form 3?
What stock option grants are reported for OKYO (OKYO) Chief Scientific Officer?
When do the reported OKYO (OKYO) options held by the CSO expire?
What are example strike prices on the OKYO (OKYO) options reported?
Does this OKYO (OKYO) Form 3 show any insider buying or selling activity?
AI-generated analysis. How Rhea-AI works. Not financial advice.
